Build 2017 Infrastructure Awards 10 ounded in 2006, Endoceutics focuses on developing non estrogen-based therapies for sexual dysfunction and the other symptoms of menopause, including hot flushes, osteoporosis, muscle loss and type 2 diabetes. Following approval by the FDA of Intrarosa™ in November 2016, Endoceutics continues to work on estrogen-free treatment of other problems of menopause. Hormonal therapies for breast, uterine and prostate cancer, male hypogonadism as well as endometriosis are also under development. Currently, Endoceutics has five Phase III product candidates addressing large market opportunities and two Phase I/II product candidates. EndoCeutics has exclusive worldwide rights to patents, patent applications, technology and know-how related to all its products. Fernand discusses the firm’s discoveries in more detail and how these help the firm to achieve its overall aim. “Here at Endoceutics, our overall aim is to be able to offer to all women around the world the benefits of an efficacious and safe treatment of all the problems of menopause, which include hot flushes, vaginal dryness, sexual dysfunction, loss of bone, loss of muscle as well as memory and cognition loss. We have a strong desire to move science forward for a better life of our fellow citizens, and this will remain our ongoing goal. “To achieve this we work hard to discover new techniques and treatments. Alongside the discovery of medical castration and combined androgen blockade which have become the standard treatment of prostate cancer which continues to help millions of men worldwide, there are 32 million women in the United States alone who could benefit from IntrarosaTM, the newly discovered and developed treatment of vulvovaginal atrophy approved in November 2016 by the FDA. IntrarosaTM is the first physiological non-estrogenic treatment for vulvovaginal atrophy. This treatment uses Prasterone (DHEA), a compound without intrinsic estrogenic or androgenic activity which is transformed intracellularly into androgens and estrogens only in the cells and vaginal layers physiologically in need of these sex steroids. This innovative treatment provides a replacement for the local deficiency in sex steroids with no significant increase in circulating estrogens or androgens and consequently, no effect in the other tissues. “In addition, positive effects are observed on the four domains of sexual dysfunction, namely desire, arousal, orgasm and pleasure, an effect secondary to local androgen formation and not found with estrogens. These observations are under further evaluation by Endoceutics.” Being based in Québec City means working in an innovative capital bursting with creativity and boasting a strong economy based on knowledge, technology, and world-class research. This environment breeds innovative companies such as EndoCeutics, which works to stay at the forefront of the latest market developments, as Fernand explains. “In order to keep ahead of this field, we will be exploring more clinical applications using the best technology which we largely developed, taking as example the mass spectrometry-based steroid assays, which have become the gold standard in the industry. Change in the therapeutic domain is central to improving the lives of women across the globe, and as such, we will continue to embrace this strategy as we seek to be the leaders of innovation in women’s health in the pharmaceutical market. “There are many challenges to remaining at the forefront of this market, since much patience is needed to start by discovery and move from the interesting discoveries up to patient’s care. One of the challenges is the large number of steps which we have to go through up to the FDA, Health Canada or other health agency approvals. Also, one of the biggest challenges in research and development is to find investment and people who believe in your project, which is not always easy.” Moving forward, Endoceutics, Inc. foresees exciting times ahead as it seeks to bring IntrarosaTM to market and potentially change the lives of millions of women around the world, as Fernand proudly concludes. Best Women’s Health Pharmaceutical Company 2017 & Award for Excellence in Breast Cancer Research - USA Endoceutics is a private pharmaceutical company operating in the field of women’s health and hormone- sensitive cancer prevention and treatment. We invited Fernand Labrie from the firm to tell us more about the firm and the vital services it offers. F IA170008 Company: Endoceutics, Inc. Contact: Fernand Labrie Contact Email:
[email protected] Address: 2795 Boulevard Laurier, #500, Ville de Québec, Quebec, G1V 4M7, Canada Phone: +1 418-653-0033 Web Address: www.endoceutics.com